Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism (Q34187120)

31 July 2017

1 reference

title

Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism (English)

1 reference

31 July 2017

Hruz PW

1

1 reference

31 July 2017

Murata H

series ordinal

2

1 reference

31 July 2017

Mueckler M

series ordinal

3

1 reference

31 July 2017

1 April 2001

1 reference

American Journal of Physiology - Endocrinology and Metabolism

31 July 2017

1 reference

31 July 2017

280

1 reference

31 July 2017

E549-53

1 reference

31 July 2017

4

1 reference

Troglitazone action is independent of adipose tissue

31 July 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Molecular cloning and characterization of an insulin-regulatable glucose transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Lipodystrophy in patients naive to HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Life without white fat: a transgenic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

The perils of portliness: causes and consequences of visceral adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Peripheral but not hepatic insulin resistance in mice with one disrupted allele of the glucose transporter type 4 (GLUT4) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Targeting the HIV-protease in AIDS therapy: a current clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

Inhibition of adipocyte differentiation by HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.2001.280.4.E549

10.1152/AJPENDO.2001.280.4.E549

21 January 2018

Identifiers

DOI

0 references

1 reference